Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Whitehawk Therapeutics, Inc. (WHWK) is the issuer in an amended Schedule 13G/A reporting that several reporting persons, including ABG V-SIV Limited and Fan Yu, may be deemed to share beneficial ownership of 4,829,398 shares, or 7.8% of the class. Fan Yu is identified as the controlling stockholder of ABG Global Life Science Capital Partners V GP Limited. The reporting persons disclaim beneficial ownership of the securities.
The reported amount includes 1,619,472 shares held of record and 3,209,926 shares issuable upon currently exercisable warrants, subject to a 9.99% beneficial ownership limitation on exercise. Whitehawk had 59,008,982 shares outstanding as of November 5, 2026.
Key Figures
Beneficial ownership reported:4,829,398 sharesPercent of class:7.8%Shares held of record:1,619,472 shares+3 more
6 metrics
Beneficial ownership reported4,829,398 sharesSeveral reporting persons may be deemed to share beneficial ownership
Percent of class7.8%As reported for the beneficially owned amount
Shares held of record1,619,472 sharesHeld of record by ABG V-SIV Limited
Shares issuable upon warrant exercise3,209,926 sharesWarrants held of record by ABG V-SIV Limited; currently exercisable
Shares outstanding59,008,982 sharesAs of November 5, 2026
Beneficial ownership limitation9.99%Limitation on exercise of the warrants
Key Terms
beneficial ownership limitation, beneficial ownership, held of record, warrants
4 terms
beneficial ownership limitationregulatory
"subject to a 9.99% beneficial ownership limitation on exercise"
A beneficial ownership limitation is a rule that caps the percentage of a company’s shares an investor can be treated as owning or controlling for voting, regulatory or tax purposes. It matters to investors because it can restrict how many shares a person or group can buy or vote, affect takeover chances, and influence share liquidity and value — like a speed limit that prevents any single driver from taking over the whole road.
beneficial ownershipregulatory
"may be deemed to share beneficial ownership of the securities"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
held of recordfinancial
"shares of Common Stock held of record by ABG V-SIV Limited"
warrantsfinancial
"warrants are currently exercisable"
Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How much beneficial ownership was reported for WHWK?
Several reporting persons may be deemed to share beneficial ownership of 4,829,398 shares, or 7.8% of the class. The amount includes shares held of record by ABG V-SIV Limited and shares issuable upon exercise of its warrants; the reporting persons disclaim beneficial ownership.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 2)
Whitehawk Therapeutics, Inc.
(Name of Issuer)
Common Stock, par value $0.0001 per share
(Title of Class of Securities)
00032Q104
(CUSIP Number)
09/30/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
00032Q104
1
Names of Reporting Persons
ABG Management Ltd.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
CAYMAN ISLANDS
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
0.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0 %
12
Type of Reporting Person (See Instructions)
CO
SCHEDULE 13G
CUSIP Number(s):
00032Q104
1
Names of Reporting Persons
Ally Bridge Group (NY) LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
0.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0 %
12
Type of Reporting Person (See Instructions)
OO
SCHEDULE 13G
CUSIP Number(s):
00032Q104
1
Names of Reporting Persons
Ally Bridge MedAlpha Master Fund L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
CAYMAN ISLANDS
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
0.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0 %
12
Type of Reporting Person (See Instructions)
PN
SCHEDULE 13G
CUSIP Number(s):
00032Q104
1
Names of Reporting Persons
ABG Global Life Science Capital Partners V GP Limited
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
CAYMAN ISLANDS
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
4,829,398.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
4,829,398.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
4,829,398.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
7.8 %
12
Type of Reporting Person (See Instructions)
CO
SCHEDULE 13G
CUSIP Number(s):
00032Q104
1
Names of Reporting Persons
ABG Global Life Science Capital Partners V GP, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
CAYMAN ISLANDS
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
4,829,398.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
4,829,398.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
4,829,398.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
7.8 %
12
Type of Reporting Person (See Instructions)
PN
SCHEDULE 13G
CUSIP Number(s):
00032Q104
1
Names of Reporting Persons
Ally Bridge Group Global Life Science Capital Partners V, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
CAYMAN ISLANDS
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
4,829,398.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
4,829,398.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
4,829,398.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
7.8 %
12
Type of Reporting Person (See Instructions)
PN
SCHEDULE 13G
CUSIP Number(s):
00032Q104
1
Names of Reporting Persons
ABG-SIV, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
CAYMAN ISLANDS
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
4,829,398.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
4,829,398.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
4,829,398.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
7.8 %
12
Type of Reporting Person (See Instructions)
PN
SCHEDULE 13G
CUSIP Number(s):
00032Q104
1
Names of Reporting Persons
ABG V-SIV Limited
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
CAYMAN ISLANDS
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
4,829,398.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
4,829,398.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
4,829,398.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
7.8 %
12
Type of Reporting Person (See Instructions)
CO
SCHEDULE 13G
CUSIP Number(s):
00032Q104
1
Names of Reporting Persons
Fan Yu
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
MALTA
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
4,829,398.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
4,829,398.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
4,829,398.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
7.8 %
12
Type of Reporting Person (See Instructions)
IN
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Whitehawk Therapeutics, Inc.
(b)
Address of issuer's principal executive offices:
2 Headquarters Plaza, East Building, 11th Floor, Morristown,NJ, 07960
Item 2.
(a)
Name of person filing:
Each of the following is hereinafter individually referred to as a "Reporting Person" and collectively as the "Reporting Persons." This statement is filed on behalf of:
ABG Management Ltd.
Ally Bridge Group (NY) LLC
Ally Bridge MedAlpha Master Fund L.P.
ABG Global Life Science Capital Partners V GP Limited
ABG Global Life Science Capital Partners V GP, L.P.
Ally Bridge Group Global Life Science Capital Partners V, L.P.
ABG-SIV, L.P.
ABG V-SIV Limited
Mr. Fan Yu
(b)
Address or principal business office or, if none, residence:
The principal business office address for Ally Bridge Group (NY) LLC is 430 Park Avenue, 12th Floor, New York, NY 10022. The principal business office address for ABG Management Ltd. and Mr. Fan Yu is Unit 3902, 39/F, East Tower Cheung Kong Center II, 10 Harcourt Road Central, Hong Kong. The principal business office address for each of the other Reporting Persons is c/o Maples Corporate Services Limited, P.O. Box 309, Ugland House, Grand Cayman, Cayman Islands.
(c)
Citizenship:
Ally Bridge Group (NY) LLC is organized under the laws of the State of Delaware. Mr. Fan Yu is a citizen of Malta. Each of the other Reporting Persons is organized under the laws of the Cayman Islands.
(d)
Title of class of securities:
Common Stock, par value $0.0001 per share
(e)
CUSIP No.:
00032Q104
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
The information contained on the cover pages to this Schedule 13G is incorporated by reference into this Item 4.
The ownership information presented herein represents beneficial ownership of the Issuer's common stock, par value $0.0001 per share ("Common Stock"), based on 59,008,982 shares of Common Stock outstanding as of November 5, 2026, as disclosed in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 9, 2026.
The amount of securities reported herein includes: (i) 1,619,472 shares of Common Stock held of record by ABG V-SIV Limited; and (ii) 3,209,926 shares of Common Stock issuable upon exercise of warrants held of record by ABG V-SIV Limited. The warrants are currently exercisable and are subject to a 9.99% beneficial ownership limitation on exercise. Ally Bridge MedAlpha Master Fund LP no longer holds shares in the Issuer.
ABG Global Life Science Capital Partners V GP Limited is the general partner of ABG Global Life Science Capital Partners V GP, L.P., which is the general partner of each of Ally Bridge Group Global Life Science Capital Partners V, L.P. and ABG-SIV, L.P., which are the shareholders of ABG V-SIV Limited.
Mr. Fan Yu is the controlling stockholder of ABG Global Life Science Capital Partners V GP Limited.
Accordingly, each of the foregoing entities and Mr. Fan Yu may be deemed to share beneficial ownership of the securities held of record by ABG V-SIV Limited. Each of them disclaims beneficial ownership of such securities.
(b)
Percent of class:
See cover pages
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
See cover pages
(ii) Shared power to vote or to direct the vote:
See cover pages
(iii) Sole power to dispose or to direct the disposition of:
See cover pages
(iv) Shared power to dispose or to direct the disposition of:
See cover pages
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
ABG Management Ltd.
Signature:
By: /s/ Fan Yu
Name/Title:
Fan Yu, Director
Date:
11/16/2026
Ally Bridge Group (NY) LLC
Signature:
By: ABG Management Ltd., its managing member, By: /s/ Fan Yu
Name/Title:
Fan Yu, Director
Date:
11/16/2026
Ally Bridge MedAlpha Master Fund L.P.
Signature:
By: Ally Bridge Group (NY) LLC, its manager, By: ABG Management Ltd., its managing member, By: /s/ Fan Yu
Name/Title:
Fan Yu, Director
Date:
11/16/2026
ABG Global Life Science Capital Partners V GP Limited
Signature:
By: /s/ Shan-ju Yeh
Name/Title:
Shan-ju Yeh, Director
Date:
11/16/2026
ABG Global Life Science Capital Partners V GP, L.P.
Signature:
By: ABG Global Life Science Capital Partners V GP Limited, its general partner, By: /s/ Shan-ju Yeh
Name/Title:
Shan-ju Yeh, Director
Date:
11/16/2026
Ally Bridge Group Global Life Science Capital Partners V, L.P.
Signature:
By: ABG Global Life Science Capital Partners V GP, L.P., ABG Global Life Science Capital Partners V GP Limited, /s/ Shan-ju Yeh
Name/Title:
Shan-ju Yeh, Director
Date:
11/16/2026
ABG-SIV, L.P.
Signature:
By: ABG Global Life Science Capital Partners V GP, L.P., ABG Global Life Science Capital Partners V GP Limited, /s/ Shan-ju Yeh